Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 09-01 11:15:27 EDT

25.43

-0.24

-0.93%

High26.33	Low25.25	Vol81.44K
Open25.47	D1 Closing25.67	Amplitude4.21%
Mkt Cap2.24B	Tradable Cap1.68B	Total Shares88.16M
T/O2.07M	T/O Rate0.12%	Tradable Shares66.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":25.43,"timestamp":1788275726215,"preClose":25.67,"halted":0,"volume":81438,"delay":0,"changeRate":-0.009349435138293805,"floatShares":66025800,"shares":88158500,"eps":-4.37633,"marketStatus":"Trading","change":-0.24,"latestTime":"09-01 11:15:27 EDT","open":25.47,"high":26.33,"low":25.25,"amount":2072660.62164,"amplitude":0.042072,"askPrice":25.43,"askSize":90,"bidPrice":25.37,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-4.37633,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":25.67,"preHourTrading":{"tag":"盘前","latestPrice":25.4789,"preClose":25.67,"latestTime":"09:18 EDT","volume":5449,"amount":139476.14585,"timestamp":1788268691707,"change":-0.1911,"changeRate":-0.007444,"amplitude":0.03584},"postHourTrading":{"tag":"盘后","latestPrice":25.73,"preClose":25.67,"latestTime":"19:56 EDT","volume":167433,"amount":4298075.582672,"timestamp":1788220575865,"change":0.06,"changeRate":0.002337,"amplitude":0.002337},"volumeRatio":0.380038,"impliedVol":0.7397,"impliedVolPercentile":0.2381},"requestUrl":"/m/hq/s/MLYS/tweets","defaultTab":"tweets","newsList":[{"id":"2662751716","title":"Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662751716","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662751716?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:02","pubTimestamp":1787745779,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics joins Wells Fargo annual healthcare conference fireside chatMineralys Therapeutics will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on Sept. 8-10,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLbHj4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","MLYS","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","BCDF","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662831718","title":"Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226","url":"https://stock-news.laohu8.com/highlight/detail?id=2662831718","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662831718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:45","pubTimestamp":1787741125,"startTime":"0","endTime":"0","summary":"Mineralys Chief Commercial Officer Eric Warren disposes of 7,437 common shares worth $193,226Mineralys Therapeutics Chief Commercial Officer Eric Warren sold 7,437 common shares on Aug. 21.Sale priced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1RgTZp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661121126","title":"Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2661121126","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661121126?lang=en_us&edition=fundamental","pubTime":"2026-08-23 00:24","pubTimestamp":1787415872,"startTime":"0","endTime":"0","summary":"Why Mineralys Therapeutics Stock Is In Focus After Earnings And Leadership Change\nMineralys Therapeutics (MLYS) is on investors’ radar after second quarter 2026 results showed a net loss of US$241.07 million, alongside the appointment of James J. Ferguson III, M.D., as Chief Medical Officer.\nSee our latest analysis for Mineralys Therapeutics.\nMineralys Therapeutics’ recent news arrives after a mixed run for investors, with the share price down 5.04% over 30 days and 14.07% over 90 days, yet a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/why-mineralys-therapeutics-mlys-is-getting-fresh-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/why-mineralys-therapeutics-mlys-is-getting-fresh-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444679","title":"Does New CMO Hire and Heavier Leverage Reshape the Bull Case For Mineralys Therapeutics (MLYS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444679","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444679?lang=en_us&edition=fundamental","pubTime":"2026-08-19 17:16","pubTimestamp":1787131013,"startTime":"0","endTime":"0","summary":"In August 2026, Mineralys Therapeutics reported a second-quarter net loss of US$241.07 million and a six-month net loss of US$280.41 million, while also appointing veteran cardiologist and drug developer James J. “Terry” Ferguson III, M.D., as its new Chief Medical Officer with his predecessor moving into a full-time advisory role.\nThese developments came as the company advanced its lead therapy lorundrostat toward an expected FDA decision and bolstered its balance sheet with US$150 million...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/does-new-cmo-hire-and-heavier-leverage-reshape-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/does-new-cmo-hire-and-heavier-leverage-reshape-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162640","title":"Mineralys Grants New CMO Inducement Awards for 135,000 Stock Options, 102,400 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162640","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162640?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:06","pubTimestamp":1786651613,"startTime":"0","endTime":"0","summary":"Mineralys grants new CMO inducement awards for 135,000 stock options, 102,400 RSUsMineralys Therapeutics granted new Chief Medical Officer Terry Ferguson inducement equity awards dated Aug. 10, 2026.P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL908CZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162321","title":"Mineralys Therapeutics Reports Inducement Award Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162321?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651504,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA2H58QJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315159","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:10","pubTimestamp":1786619422,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monte Rosa Therapeutics (GLUE), Mineralys Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-mineralys-therapeutics-inc-mlys-and-adagene-adag-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-mineralys-therapeutics-inc-mlys-and-adagene-adag-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLYS","BK4581","GLUE","LU0029874061.USD","BK4588","XLV","HCSG","XBI","BK4139","BK4137","LU0128526141.USD","BK4539","ADAG","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135482","title":"Mineralys Therapeutics Confronts Heightened Refinancing and Liquidity Risks as 2031 Debt Maturity Looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135482?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:00","pubTimestamp":1786600839,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. (MLYS) has disclosed a new risk, in the Debt & Financing category. Mineralys Therapeutics, Inc. faces material refinan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-confronts-heightened-refinancing-and-liquidity-risks-as-2031-debt-maturity-looms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mineralys-therapeutics-confronts-heightened-refinancing-and-liquidity-risks-as-2031-debt-maturity-looms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MLYS","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189827","title":"Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189827","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189827?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:33","pubTimestamp":1786577635,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics CMO David Malcom Rodman disposes of USD 58,785.3 in common sharesMineralys Therapeutics Chief Medical Officer Rodman David Malcom exercised stock options for 2,170 shares at USD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4jh0hD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 58,785.3 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189821","title":"Mineralys Therapeutics Names James J. Ferguson III as Chief Medical Officer in Form 3 Beneficial Ownership Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189821","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189821?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:33","pubTimestamp":1786577632,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics names James J. Ferguson III as chief medical officer in Form 3 beneficial ownership filingMineralys Therapeutics filed a Form 3 initial beneficial ownership statement for Chief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbSLqXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658778359","title":"Goldman Sachs Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658778359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658778359?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:20","pubTimestamp":1786537233,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Richard Law CFA maintained a Buy rating on Mineralys Therapeutics, Inc. today and set a price target of $40.00. Law CFA cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-reaffirms-their-buy-rating-on-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-reaffirms-their-buy-rating-on-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928337","title":"Mineralys Therapeutics Publishes Corporate Presentation on Lorundrostat for Uncontrolled, Resistant Hypertension and Cardiorenal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928337?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:14","pubTimestamp":1786504440,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics publishes corporate presentation on lorundrostat for uncontrolled, resistant hypertension and cardiorenal diseasesMineralys highlighted FDA acceptance of its NDA for lorundrosta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL2vf24g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945272","title":"Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945272","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945272?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:01","pubTimestamp":1786482072,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryMineralys Therapeutics, Inc.MLYS.OQreported a quarterly adjusted loss of $2.85 per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448261:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658294596","title":"Mineralys Therapeutics Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2658294596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658294596?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:46","pubTimestamp":1786481180,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  reported a Q2 loss late Tuesday of $2.85 per diluted share, widening from a loss of $0.66 a year earlier.Analysts polled by FactSet expected a loss of $0.55.As expected, no revenue was reported for the quarter ended June 30.Cash and cash equivalents as of June 30 were $661.4 million, which is expected to fund operations into 2028, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","MLYS","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658432299","title":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658432299","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658432299?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:29","pubTimestamp":1786480180,"startTime":"0","endTime":"0","summary":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948073","title":"Mineralys Therapeutics Catat Rugi Bersih Kuartal II FY26 Melebar Jadi USD 241,07 Juta; Belanja R&D Melonjak Jadi USD 221,38 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948073","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948073?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479051,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics catat rugi bersih kuartal II FY26 melebar jadi USD 241,07 juta; belanja R&D melonjak jadi USD 221,38 jutaMineralys membukukan rugi bersih USD 241,07 juta pada kuartal II 2026, m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8ftqbz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","LU2095319765.USD","BK4112","SG9999014021.USD","BCDF","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","BK4588","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","LU0314104364.USD","IE00B64PRP62.GBP","MLYS","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658484179","title":"Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658484179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658484179?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478700,"startTime":"0","endTime":"0","summary":"Administration  continues its review of the NDA for lorundrostat for. the treatment of hypertension in combination with other antihypertensive. drugs, with a Prescription Drug User Fee Act  target date of. -- Appointment of New Chief Medical Officer  -- Appointed James J.\"Terry\" Ferguson III, M.D., as CMO, effective August 10, 2026, succeeding. David Rodman, M.D., who will stay on with the Company as a full-time. Strategic Advisor. Terry brings more than 35 years of experience in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555653","title":"Mineralys Therapeutics to Report Q2 Results, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555653?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:04","pubTimestamp":1785845089,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics to report Q2 results, host conference callMineralys schedules second-quarter 2026 results release for Aug. 11, 2026, following the U.S. market close.Conference call set for Aug.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbQlDd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","MLYS","IE00BN0W2V16.EUR","NDAQ","BCDF","BK4139","BK4112","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654040921","title":"Mineralys Therapeutics Grants Inducement Equity Awards to New Hires Under 2025 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654040921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654040921?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:01","pubTimestamp":1785182492,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics grants inducement equity awards to new hires under 2025 planMineralys Therapeutics granted inducement equity awards to two new non-executive employees under its 2025 Employment ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL98K9mt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","MLYS","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654919040","title":"Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654919040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654919040?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:01","pubTimestamp":1785182460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA22PBRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0059},{"period":"3month","weight":-0.1102},{"period":"6month","weight":-0.1078},{"period":"1year","weight":0.6583},{"period":"ytd","weight":-0.2926}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.095856},{"month":4,"riseRate":0,"avgChangeRate":-0.078413},{"month":5,"riseRate":1,"avgChangeRate":0.100473},{"month":6,"riseRate":0.25,"avgChangeRate":-0.046559},{"month":7,"riseRate":0.5,"avgChangeRate":-0.030144},{"month":8,"riseRate":0.75,"avgChangeRate":0.002547},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction